CSTL (Castle Biosciences) Institutional Ownership: 98.29% (As of Jul. 09, 2026)


CSTL Castle Biosciences Inc CSTL
77 GF Score
Price $24.35
GF Value $29.19
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Institutional Ownership?

Castle Biosciences CSTL +2.98% 77 Institutional Ownership is 98.29% as of Jul. 09, 2026. GuruFocus rates CSTL with a GF Score™ of 77/100 and a GF Value™ of $29.19 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Castle Biosciences's institutional ownership is 98.29%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Castle Biosciences's Insider Ownership is 2.32%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Castle Biosciences's Float Percentage Of Total Shares Outstanding is 97.64%.

Castle Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences Institutional Ownership Chart

Castle Biosciences Historical Data

The historical data trend for Castle Biosciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 62.76 61.82 58.95 59.79 58.54 57.67 55.88 54.93 53.96 54.45
CSTL
77GF Score
Castle Biosciences Inc CSTL
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 98.29% mean?
Castle Biosciences (CSTL) has a Institutional Ownership of 98.29% as of Jul. 09, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Castle Biosciences and its competitors.
Is Castle Biosciences' Institutional Ownership too high?
Castle Biosciences' current Institutional Ownership is 98.29%. Overall, Castle Biosciences has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Institutional Ownership compare to FLGT and MYGN?
Castle Biosciences' Institutional Ownership of 98.29% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Diagnostics & Research company?
A good Institutional Ownership depends on the Medical Diagnostics & Research industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Institutional Ownership is 98.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.19, compared to a current price of $24.35 — trading 16.6% below its estimated fair value. The current Institutional Ownership is 98.29%. Castle Biosciences' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Institutional Ownership is 98.29% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $24.35 is trading 16.6% below its estimated GF Value™ of $29.19. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • Institutional Ownership: 98.29%
  • GF Value™: $29.19 vs. price of $24.35 (16.6% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
77GF Score

Get the complete analysis for CSTL

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.35
Price
$29.19
GF Value